Azelastine Allergen Chamber - Onset of Action Study
Status:
Completed
Trial end date:
2024-03-18
Target enrollment:
Participant gender:
Summary
This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in
treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen
challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day
treatment at home.